Compare Cronos Group Inc (CRON) vs CSX Corporation (CSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs CSX Corporation — how do they compare? Cronos Group Inc trades at $3.22 (market cap $1.18B), while CSX Corporation trades at $47.3 (market cap $87.70B). The key difference: CSX Corporation is far larger — about 74.3× Cronos Group Inc's market cap, and CSX Corporation pays a 1.18% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and CSX Corporation for 55 Days on average.
| CRON | CSX | |
|---|---|---|
Market Cap | $1.18B | $87.70B |
Volume | 968,037 | 6,980,781 |
Sector | Health | Industrials |
52-Week High | $3.55 | $53.21 |
52-Week Low | $2.30 | $33.68 |
Typical Hold Time | 22 Days | 55 Days |
Enterprise Value | $387.62M | $105.66B |
Dividend Yield | — | 1.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.23, down 0.31% with a bearish technical signal. Recent earnings show volatility with Q2 2026 beating expectations ($0.09 vs $0.01) but Q4 2025 missing. Revenue grew from $118M (2024) to $147M (2025), though net income turned negative at -$9M. The company maintains strong liquidity with $827M cash and no debt, highlighted in recent investor day presentations.
Outlook is mixed: analyst consensus leans Hold (60%) with cautious optimism on international expansion and margin improvements. Key risks include sustained negative cash flow (-$67M in 2025) and competitive pressures. Upside hinges on execution of growth initiatives in Canada and Europe, with profitability projections for 2026.
CSX trades at $47.26, up 0.96% with a bullish technical signal. The stock shows strong profitability with 22.21% net margin and 24.37% ROE, though revenue declined to $14.09B in 2025. Recent Q2 2026 earnings beat expectations at $0.54 vs $0.518. Analyst consensus is bullish with 58.69% buy ratings and $51.00 price target. The company maintains stable cash flow operations and recently announced a $0.14 dividend payable September 2026.
CSX presents a favorable investment case with strong fundamentals and analyst support, though valuation metrics appear elevated. Key risks include revenue pressure and competitive threats. The upcoming Q3 2026 earnings on October 21 will be critical for confirming the positive trend. Current levels offer potential upside to consensus targets but require monitoring of operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
